Mayo Clinic and Thermo Fisher Formed Precure

The new biotech entity aims to generate a massive biomedical dataset using molecular data from one million samples.

Updated on Sept. 21, 2026 in Biotech

Isometric editorial illustration showing a single glass specimen vial, representing biotech data collection. — Mayo Clinic and Thermo Fisher Scientific have launched Precure, a new biotech company dedicated to building a massive biomedical dataset for precision medicine. AI Illustration. Upload story photo >

Live Poll

Do you believe large-scale biomedical data collection will lead to better healthcare outcomes?

The Mayo Clinic and Thermo Fisher Scientific have established a new company called Precure to develop a comprehensive biomedical dataset. By analyzing molecular information from one million biospecimens, the company intends to drive the creation of new diagnostic tools and therapies.

Why it matters

Precure aims to generate population-scale molecular data, which is essential for advancing precision medicine and developing targeted healthcare products. This collaboration combines large-scale clinical research with advanced analytics to identify patterns that could improve future patient outcomes.

Precure utilizes artificial intelligence and large-scale data analytics to process molecular information derived from blood, urine, saliva, and stool samples. The project aims to construct a multi-omics and phenotype dataset over a five-year period.

The players

Mayo Clinic

This Rochester-based nonprofit academic medical center is the majority owner of Precure and provides the clinical foundation for the research study.

Thermo Fisher Scientific

This biotechnology company is a minority owner of Precure and maintains a long-standing collaborative history with the Mayo Clinic.

Regeneron Pharmaceuticals

This biotechnology company is providing the necessary funding for the ongoing Precure study involving 100,000 participants.

The details

As the majority owner, the Mayo Clinic leverages its clinical infrastructure to power the Precure study, which is funded by Regeneron Pharmaceuticals. The study, which began in early 2026, focuses on gathering deep biological insights to fuel innovation in the biotech sector.

2021: Thermo Fisher and Mayo Clinic formed a prior partnership to validate diagnostic tools.
January 2026: Mayo Clinic started the Precure prospective study.
July 2026: Mayo Clinic launched Precure Research.
September 2026: The partners officially unveiled the company Precure.

Healthcare
Sept. 24
Malta Explored Healthcare Ties With Mayo Clinic
Healthcare
Sept. 23
Governor Walz Visited Rochester Medical Site
Philanthropy
Sept. 20
Walk to Defeat ALS Raised $62,000 in Rochester

The Tech Race

The creation of Precure represents a significant consolidation of institutional clinical data and analytical technology in the competitive race for precision health. It signals a shift from singular diagnostic validation projects toward the building of massive, multi-year, multi-omic repositories.

While the project is in its early stages, the development of these diagnostic and therapeutic tools aims to eventually provide more accurate medical treatments for the public. Participants in the Rochester area and beyond may see increased opportunities to contribute to large-scale clinical studies as the dataset grows.

The takeaway

This partnership highlights how major medical institutions are increasingly relying on AI-driven analytics to unlock the potential of large-scale bio-repositories. Readers can anticipate a growing focus on data-backed precision medicine in the coming years as these datasets mature.